Navigation Links
Detke Joins MedAvante as Chief Medical Officer
Date:3/12/2009

Former Eli Lilly executive Michael J. Detke, MD, PhD, is frequent presenter on the causes of failed clinical studies for central nervous system (CNS) therapeutics and methods for improvement

HAMILTON, N.J., March 12 /PRNewswire/ -- MedAvante, Inc. the leader in centralized psychiatric patient evaluation, announced today that Michael Detke, MD, PhD, has joined the company as Chief Medical Officer and Director of the MedAvante Research Institute. Dr. Detke comes to MedAvante from Eli Lilly, Inc., in Indianapolis, Indiana, where he was Executive Director and head of early phase development of CNS therapeutics.

"We are honored to have Michael join our team," says Paul Gilbert, Chief Executive Officer of MedAvante. "At Lilly, Mike led early phase development of one of the industry's deepest and strongest pipelines of CNS products. His earlier work on Cymbalta(R) and Prozac(R) proves that he is a top-caliber scientist dedicated to developing CNS therapeutics. At MedAvante, Mike will apply his leadership abilities, scientific expertise, and commitment to quality assurance to help us deliver our leading-edge methodology for removing sources of bias and variability, increasing signal detection, and reducing the high rate of failed CNS trials."

Dr. Detke says, "MedAvante holds great promise for ensuring the future success of CNS therapeutics. For decades and now acutely, our industry has struggled with the problems of rater bias and an inability to separate placebo response from active-drug response. MedAvante offers a potential powerful solution for these problems. Our methodology to substantially increase the efficiency of clinical studies can help bring new treatments to market for patients suffering from debilitating CNS diseases. Furthermore, it can help to elucidate efficacy further, to help patients and doctors understand, for example, the relative efficacy of different drugs for a disorder, or different doses of a drug."

Prior to joining MedAvante, Dr. Detke worked for Eli Lilly Research Laboratories in Indianapolis, for more than 8 years, most recently as Executive Director overseeing all CNS products in early phase development for psychiatry, neurology and pain indications. He is Associate Clinical Professor of Psychiatry at Indiana University School of Medicine, where he teaches and supervises medical students and residents in patient care. He is Research Associate at Harvard Medical School. He has been the principal investigator in numerous studies of CNS therapeutics. Dr. Detke has published more than 50 articles in peer-reviewed journals, and has served as a reviewer for numerous such journals. He is a member in prestigious scientific organizations such as ACNP and SOBP. He graduated summa cum laude with a BA and MS in Psychology at Yale University and his MD and PhD at the University of Pennsylvania; he completed his medical internship and psychiatry residency at Harvard University.

About MedAvante, Inc

MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante's two-way, real-time, high-quality videoconferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, New Jersey; Los Angeles, California; and Madison, Wisconsin. MedAvante is backed by over $34 million in investor financing including $20 Million in growth financing by Goldman Sachs and Trevi Health Ventures. For more information about MedAvante, visit www.medavante.net.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jocelyn Frederick Joins Tsoi/Kobus & Associates as Principal
2. Michael J. Fox Foundation Joins Effort to Recruit 10,000 People With Parkinsons Disease to New Web-Based PD Research Community
3. Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania
4. KevinMD.com Joins the HCPLive.com Network
5. Rehab Specialist, Michael Fisher, Joins Fast - Growing Alliance Seating & Mobility in North Carolina
6. Nurse & Veteran Rehab Specialist, Terri Witten, Joins Fast-Growing Alliance Seating & Mobility in Ohio
7. Veteran Rehab Specialist, Donna Cole, Joins Fast-Growing Alliance Seating & Mobility in California
8. Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan
9. Wound Management Technologies Joins IMCO Vendor Network to Expand Sales Nationwide
10. Michael Forte Joins CONNEXION Healthcare as Chief Operations Officer
11. Julie Gallagher Joins Akerman Senterfitts Healthcare Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... Dublin, CA (PRWEB) , ... December 06, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... Health Fundamentals certificate program focused on providing occupational safety and health training to ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham ... announce the arrival of the newest Sciton laser in January 2017. The Halo ... tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016  Sharn Anesthesia ... preferred anesthesia sales and distribution partner for Salter Labs.  ... of the Year in recognition of outstanding sales performance. ... devices for respiratory and anesthesia care, including the market ... is also the master distributor of the Parker Flex-Tip® ...
(Date:12/5/2016)... TrainerMD , the first HIPAA compliant software collaboration platform for patients, ... . Styku, a California -based software ... world-class, real-time 3D body scanning and analysis. Together with its other ... and feel their health like never before. ... , , ...
Breaking Medicine Technology: